UCP2 -866G>A (rs659366) has been implicated in cardiometabolic disease and represents a novel candidate gene for beta-blocker response, particularly among patients with diabetes. We assessed the function of -866G>A and its role as a modifier of beta-blocker treatment outcomes by diabetes status in an acute coronary syndrome (ACS) cohort.
Endocrinology, Diabetes and Nutrition Division, University of Maryland School of Medicine, 660 W. Redwood Street, Baltimore, MD 21201, USA. abeitels@medicine.umaryland.edu